BioCentury
ARTICLE | Financial News

Sofinnova Partners, 5AM lead £28 million NodThera series A

June 29, 2018 3:02 PM UTC

Inflammation company NodThera Ltd. (Cambridge, U.K.) raised £28 million ($37 million) in a tranched series A led by Sofinnova Partners and 5AM Ventures. Epidarex Capital, which founded NodThera in 2016, and F-Prime Capital Partners also participated.

Spun out of Selvita S.A. (Warsaw:SLV), NodThera is developing next-generation NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) inhibitors for inflammation-driven diseases. Although NodThera has not yet named a lead indication, the company plans to pursue inflammatory diseases as well as neurodegenerative diseases and cancers affected by chronic inflammation...